Want to see IN:TATVA full AI Analyst Report?
Top Page
Tatva Chintan Pharma Chem Limited
(TATVA)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹1,315.00
▼(-5.28% Downside)
Action:Reiterated
Date:05/22/26
The score is primarily held back by weak cash-flow quality (negative free cash flow) and volatile profitability, despite a solid balance-sheet position. Technicals are also weak with the stock trading below major moving averages and subdued momentum. Valuation is a further headwind due to the high P/E and minimal dividend yield.
Positive Factors
Conservative balance sheet
A large equity base (7.82B) against modest debt (1.20B) gives the company financial flexibility to fund investments, withstand operating shocks and support working-capital needs while free cash flow recovers. Improved leverage since earlier years reduces solvency risk and preserves optionality for capex or strategic moves.
Negative Factors
Persistent negative free cash flow
Repeated negative free cash flow, including -841M in FY2026, signals weak cash conversion of profits and/or heavy reinvestment and working-capital strain. Persistent FCF deficits force dependence on the balance sheet to fund operations and capex, constraining dividends, deleveraging, or bolt-on investments until cash conversion materially improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A large equity base (7.82B) against modest debt (1.20B) gives the company financial flexibility to fund investments, withstand operating shocks and support working-capital needs while free cash flow recovers. Improved leverage since earlier years reduces solvency risk and preserves optionality for capex or strategic moves.
Read all positive factors
Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹30.92B
Dividend Yield0.07%
Average Volume (3M)12.52K
Price to Earnings (P/E)77.4
Beta (1Y)1.11
Revenue Growth32.18%
EPS Growth636.02%
CountryIN
Employees689
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)17.98
Shares Outstanding23,392,056
10 Day Avg. Volume25,333
30 Day Avg. Volume12,516
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.15
Price to Sales (P/S)4.87
P/FCF Ratio-29.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27
Revenue Forecast (FY)₹6.21B
Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model
Company Description
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for ...
How the Company Makes Money
Tatva Chintan primarily makes money by manufacturing and selling specialty chemicals to industrial customers. Its revenue model is product-sales driven: customers (typically chemical, pharmaceutical, agrochemical, and battery-material manufacturer...
Tatva Chintan Pharma Chem Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
77
Positive
Cash Flow
34
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.06B | 3.83B | 3.94B | 4.24B | 4.34B |
| Gross Profit | 1.82B | 1.84B | 2.11B | 1.91B | 2.32B |
| EBITDA | 967.07M | 342.13M | 689.34M | 676.30M | 1.08B |
| Net Income | 420.54M | 57.13M | 303.54M | 454.87M | 958.74M |
Balance Sheet | |||||
| Total Assets | 10.04B | 8.36B | 8.19B | 7.56B | 6.58B |
| Cash, Cash Equivalents and Short-Term Investments | 87.91M | 117.01M | 456.68M | 412.15M | 638.19M |
| Total Debt | 1.20B | 363.88M | 142.71M | 1.70B | 1.20B |
| Total Liabilities | 2.22B | 974.25M | 816.36M | 2.42B | 1.85B |
| Stockholders Equity | 7.82B | 7.39B | 7.37B | 5.15B | 4.73B |
Cash Flow | |||||
| Free Cash Flow | -841.44M | -516.01M | -304.71M | -1.75B | -687.79M |
| Operating Cash Flow | 296.30M | 246.71M | 980.44M | 277.83M | 203.78M |
| Investing Cash Flow | -1.17B | -652.54M | -1.21B | -1.01B | -1.97B |
| Financing Cash Flow | 816.19M | 165.66M | 305.19M | 377.95M | 2.35B |
Tatva Chintan Pharma Chem Limited Technical Analysis
Positive
1388.35
Price Trends
1227.66
Positive
1210.81
Positive
1259.09
Positive
Market Momentum
26.33
Negative
68.42
Neutral
81.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Positive. The current price of 1388.35 is above the 20-day moving average (MA) of 1221.95, above the 50-day MA of 1227.66, and above the 200-day MA of 1259.09, indicating a bullish trend. The MACD of 26.33 indicates Negative momentum. The RSI at 68.42 is Neutral, neither overbought nor oversold. The STOCH value of 81.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TATVA.
Tatva Chintan Pharma Chem Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹100.22B | 54.08 | ― | 0.62% | -2.29% | -3.26% | |
67 Neutral | ₹138.33B | 31.17 | ― | 0.48% | -0.95% | 9.51% | |
64 Neutral | ₹29.12B | 19.61 | ― | 0.09% | 15.19% | 9.27% | |
56 Neutral | ₹115.12B | 41.68 | ― | 0.74% | 5.04% | 11.10% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹30.92B | 77.39 | ― | 0.07% | 32.18% | 636.02% | |
45 Neutral | ₹175.61B | 41.86 | ― | 0.26% | 14.15% | 26.69% |
* General Sector Average
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,390.10
459.22
49.33%
IN:AARTIIND
AARTI Industries Ltd
483.90
41.78
9.45%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,906.10
-330.13
-14.76%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
731.70
-71.29
-8.88%
IN:ROSSARI
Rossari Biotech Ltd
528.00
-169.48
-24.30%
IN:VINATIORGA
Vinati Organics Limited
1,333.90
-603.76
-31.16%
Tatva Chintan Pharma Chem Limited Corporate Events
Tatva Chintan Closes Trading Window Ahead of Q1 FY27 Results
Jun 23, 2026
Tatva Chintan Pharma Chem Limited has announced the closure of its trading window for designated persons and their immediate relatives from 1 July 2026 until 48 hours after the declaration of its unaudited financial results for the quarter ending ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.